Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of neoadjuvant docetaxel + 5-fluorouracil + cisplatin followed by cisplatin chemoradiotherapy versus standard cisplatin chemoradiotherapy in locally advanced head and neck squamous cell carcinoma
2005-001623-11Phase 2Completed
- Sponsor
- National Institute of Oncology
- Start
- Dec 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, cisplatin and fluorouracil in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by National Institute of Oncology. Primary endpoint: Local tumor control. Started Dec 2005; status: completed.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2005-001623-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001623-11.